Eli Lilly and Company to Raise Nearly $750 Million to Share Drug Development Costs
PBR -- Eli Lilly intends to raise nearly $750m through three funds to share drug development costs and potential benefits, as part of its plans to find new ways to improve the high failure rates and costs of drugs as generic competition with pricing pressures threatening its existing products.